Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Female~* Increased inherited risk of breast cancer, as defined by:~  * Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation~ * Family history conveying at least a 2-fold increase in breast cancer risk~* ECOG performance status 0~* Normal organ and marrow function, including complete blood count and comprehensive metabolic panel within normal institutional limits~* Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks per week.~EXCLUSION CRITERIA~* Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage III or lower breast cancer \> 2 years ago)~* Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III or cancer without evidence of recurrence for 5 years~* Initial mammogram, breast MRI, or clinical breast examination prompts recommendation for biopsy by study investigators.~* Evidence of malignant cytology on initial rpFNA.~* Use of other investigational agents.~* Use of tamoxifen or selective estrogen response modifiers (SERMS), including raloxifene, within the last 2 years.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.~* Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates or niacin, (unless discontinued for study participation)~* No evidence of active liver disease, nor elevation of serum transaminases (prior history of liver disease, if not currently active, is not an exclusion)~* No evidence of myopathy or myositis, including symptoms of generalized muscle aches or weakness, muscle tenderness, or elevation in creatine phosphokinase.~* Lactating (breastfeeding)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lovastatin 80 mg/day (Type: EXPERIMENTAL): Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).